Heterocyclic GSK-3 allosteric modulators

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9757369
APP PUB NO 20170196850A1
SERIAL NO

15415188

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS(CSIC)

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ayuso-Gontan, Carmen Gil Madrid, ES 3 0
Martinez, Gil Ana Madrid, ES 18 10
Palomo, Ruiz Valle Madrid, ES 4 0
Perez, Fernandez Daniel I Madrid, ES 3 0
Perez, Martin Concepcion Madrid, ES 3 0
Reyes, Rodriguez Julio Alberto Madrid, ES 3 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00